Clinical Trials — Thoracic Cancer

                                                                                            Click on trial for description and contact information.

A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) when administered to Patients with Advanced Solid Tumors

A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and/or Refractory Stage IIIB (with Malignant Pleural or Pericardial Effusion), or Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients (This study is ongoing but currently not recruiting patients.)

A Phase I/II Study of Anti-Tumor Vaccination Using a(1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer

A Phase I Dose-Finding Study of the Anti-Angiogenesis Agent AG-013736, in Combinations of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, and Gemcitabine/Cisplatin in Patients with Advanced Solid Tumors

FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung Cancer

For more information or to refer a patient, contact:

Pam Bourbo, RN, MPH, OCN, CCRC

manager

Cancer Clinical Research Unit

(706) 721-2730

pbourbo@mcg.edu